China’s National Medical Products Administration, the main regulatory body in the sector, has approved the commercialization and use of the Cuban humanized monoclonal antibody Nimotuzumab for the treatment of pancreatic cancer. The decision is based on positive results from clinical studies, the drug’s efficacy in inhibiting the growth of malignant cells, and its successful use since 1998 in Cuba and other countries.